In vitro and In vivo imaging of antivasculogenesis induced by Noggin protein expression in human venous endothelial cells.
Noggin protein is a potent bone morphogenetic protein (BMP) antagonist capable of inhibiting vasculogenesis even in the presence of provasculogenic VEGF and FGF-2. We found that human umbilical vein endothelial cells (HUVECs) do not express Noggin in culture and used these cells for modeling of antivasculogenesis. We hypothesized that high-efficiency transduction of HUVECs with bicistronic lentiviral vector encoding Noggin and enhanced green fluorescent protein (EGFP) enables direct visualization of Noggin effects in homogenous primary cell populations in vitro and in vivo. By comparing HUVECs transduced with a control GFP and GFP/Noggin expression cassettes, we showed that constitutive and orthotopic Noggin protein expression did not influence cell proliferation, down-regulated BMP-2 expression, and showed no effect on BMP receptor transcripts. We demonstrated that in contrast to GFP-only control, Noggin expression in endothelial cells abrogated endothelial migration in response to monolayer injury, blocked endothelial transmigration, and caused abrogation of cord formation in vitro. Adding exogenous BMP-4 restored the formation of cords. Imaging experiments in vivo investigated vessel formation in Matrigel implants in athymic mice by utilizing GFP imaging or magnetic resonance imaging of perfusion in the implants. Both approaches demonstrated the lack of functional vessel formation after the adoptive transfer of GFP/Noggin-expressing human endothelial cells in mice.
Kang
Hye-Won
HW
Department of Radiology, University of Massachusetts Medical School, 55 Lake Ave. North, Worcester, MA 01655, USA.
Walvick
Ronn
R
Bogdanov
Alexei
A
D000818:Animals; D055396:Bone Morphogenetic Protein 2 / Q000378:metabolism; D055415:Bone Morphogenetic Protein 4 / Q000494:pharmacology; D052004:Bone Morphogenetic Protein Receptors / Q000378:metabolism; D002352:Carrier Proteins / Q000235:genetics* / Q000378:metabolism*; D002465:Cell Movement; D049109:Cell Proliferation; D002478:Cells, Cultured; D042783:Endothelial Cells / Q000378:metabolism*; D006801:Humans; D051379:Mice; D018919:Neovascularization, Physiologic / Q000502:physiology*; D014471:Umbilical Veins; D000099176:Noggin Protein
D055396:Bone Morphogenetic Protein 2; D055415:Bone Morphogenetic Protein 4; D052004:Bone Morphogenetic Protein Receptors; D002352:Carrier Proteins; D000099176:Noggin Protein
Mol Cell Biol. 2003 Aug;23(16):5664-79
12897139
Clin Chem. 2003 Jan;49(1):32-40
12507958
Cytokine Growth Factor Rev. 1998 Mar;9(1):49-61
9720756
Dev Biol. 1998 May 15;197(2):205-17
9630747
J Virol Methods. 2004 Dec 15;122(2):131-9
15542136
Dev Biol. 2009 Feb 1;326(1):101-11
19041859
Mol Cancer Res. 2004 Mar;2(3):141-9
15037653
Arterioscler Thromb Vasc Biol. 2009 Feb;29(2):254-60
19023092
Pharm Res. 2007 Jun;24(6):1186-92
17373582
Am J Pathol. 2002 May;160(5):1629-37
12000715
Dev Cell. 2004 May;6(5):699-708
15130494
Bioconjug Chem. 2002 Jan-Feb;13(1):122-7
11792187
J Immunol. 2000 Jan 1;164(1):452-62
10605042
Exp Biol Med (Maywood). 2007 Jun;232(6):833-43
17526776
Mol Cell Biol. 2003 Jul;23(13):4627-36
12808102
Arterioscler Thromb Vasc Biol. 2009 May;29(5):718-24
19213939
Dev Biol. 2002 Oct 15;250(2):231-50
12376100
Nature. 2003 Mar 20;422(6929):317-22
12646922
Circulation. 2007 Sep 11;116(11):1258-66
17785623
Cancer Res. 2004 Feb 1;64(3):994-9
14871830
Nature. 2004 Mar 11;428(6979):138-9
15014486
Stem Cells. 2008 Nov;26(11):2810-20
18772316
Dev Biol. 2005 Apr 1;280(1):100-10
15766751
Ann N Y Acad Sci. 2006 Apr;1068:19-25
16831902
Cancer Res. 2005 Oct 15;65(20):9253-60
16230386
Nature. 2002 Dec 12;420(6916):636-42
12478285
Int J Cancer. 1999 Dec 10;83(6):798-802
10597197
Lab Invest. 2006 Jun;86(6):599-609
16607378
Cell. 1992 Sep 4;70(5):829-40
1339313
Klin Padiatr. 1997 Jul-Aug;209(4):265-70
9293460
J Neurosci. 2008 Sep 10;28(37):9194-204
18784300